SVG 301
Alternative Names: SVG-301Latest Information Update: 03 Nov 2022
At a glance
- Originator SoVarGen
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Brain cancer
Most Recent Events
- 08 Sep 2022 SVG 301 is available for licensing as of 08 Sep 2022. http://www.sovargen.com/rd#section1
- 08 Sep 2022 Early research in Brain cancer in South Korea (unspecified route) (SoVarGen pipeline, September 2022)